Pharmanovia
Pharmanovia, a leading pharmaceutical company headquartered in Great Britain, has established itself as a key player in the global healthcare landscape since its founding in 2015. With a focus on specialty pharmaceuticals, the company operates across Europe, the Middle East, and Africa, delivering innovative solutions that address unmet medical needs. Pharmanovia's core offerings include a diverse portfolio of products in therapeutic areas such as oncology, neurology, and rare diseases. What sets Pharmanovia apart is its commitment to enhancing patient access to high-quality medicines through strategic partnerships and a robust supply chain. The company has achieved notable milestones, including the successful launch of several proprietary products, solidifying its market position as a trusted provider in the pharmaceutical industry.
DitchCarbon Score
How does Pharmanovia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharmanovia's score of 16 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmanovia's reported carbon emissions
In 2023, Pharmanovia reported total carbon emissions of approximately 15,827,000 kg CO2e. This figure includes 60,000 kg CO2e from Scope 1 emissions, no emissions from Scope 2, and about 4,493,000 kg CO2e from Scope 3 emissions. The company has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 greenhouse gas emissions by 42% by 2030, using 2021 as the baseline year. This target has been validated through the Science Based Targets initiative (SBTi) and aligns with the necessary reductions to limit global warming to 1.5°C. Pharmanovia is also committed to measuring and reducing its Scope 3 emissions, which represent a significant portion of its overall carbon footprint. In 2022, Pharmanovia's total emissions were approximately 12,477,000 kg CO2e, with Scope 1 emissions at 60,000 kg CO2e, Scope 2 at 3,000 kg CO2e, and Scope 3 at about 3,172,000 kg CO2e. The increase in total emissions from 2022 to 2023 highlights the ongoing challenges in managing carbon outputs, particularly in the pharmaceutical sector. Pharmanovia's commitment to sustainability reflects its recognition of the importance of addressing climate change and its impact on the environment.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 51,000 | 00,000 | 00,000 |
| Scope 2 | 76,000 | 0,000 | - |
| Scope 3 | 9,998,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pharmanovia is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
